The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats

Cardiovascular Research

Volumn 31, Issue 4, 1996, Pages 568-576

  Sladek, Tomas ^a   Sladkova, Jarmila ^a   Kolar, Frantisek ^a,b   Papousek, Frantisek ^a,b   Cicutti, Nicholas ^a   Korecky, Borivoj ^a   Rakusan, Karel ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

angiogenesis; angiotensin receptor; hypertrophy; losartan; microcirculation; myocardial infarction; RAAS; rat, anesthetized

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LOSARTAN; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR; BIPHENYL DERIVATIVE; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORONARY ARTERY LIGATION; HEART HYPERTROPHY; HEART INFARCTION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; ANGIOGENESIS; ANIMAL; BLOOD PRESSURE; CAPILLARY; CORONARY BLOOD VESSEL; DRUG ANTAGONISM; DRUG EFFECT; HEART; HEART VENTRICLE PRESSURE; SPRAGUE DAWLEY RAT;

ANGIOTENSIN I; ANIMALS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CAPILLARIES; CORONARY VESSELS; HEART; IMIDAZOLES; LOSARTAN; MALE; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VENTRICULAR PRESSURE;

EID: 0029665837     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/0008-6363(95)00244-8     Document Type: Article

References (35)

1. Vaughan DE, Pfeffer MA. Angiotensin converting enzyme inhibitors and cardiovascular remodelling. Cardiovasc Res 1994;128:159-165.
2. Anversa P, Li P, Zhang X, Olivetti G, Capasso JM. Ischemic myocardial injury and ventricular remodelling. Cardiovasc Res 1993;27:145-157.
3. Jugdutt BI. Prevention of ventricular remodelling post myocardial infarction: timing and duration of therapy. Can J Cardiol 1993;9:103-114.
4. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 1991;260 (Heart Circ. Physiol. 29):H1406-H1414.
5. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 1991;260 (Heart Circ. Physiol. 29):H1406-H1414.
6. Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair and remodeling. Hypertension 1994;23:258-268.
7. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental infarction: beneficial effects of long-term therapy with captopril. Circulation 1985;72:406-412.
8. Strauer BE, Vogt M, Motz W. ACE-inhibitors and coronary microcirculation. In: Groebecker H, Heusch G, Strauer BE, eds. Angiotensin and the Heart. Darmstadt: Steinkopff Verlag, 1993:97-106.
9. Unger T, Gohlke P. Converting enzyme inhibitors in cardiovascular therapy: current status and future potential. Cardiovasc Res 1994;28:146-158.
10. Anversa P, Beghi C, Kikkawa Y, Olivetti G. Myocardial infarction in rats. Infarct size, myocyte hypertrophy and capillary growth. Circ Res 1986;58:26-37.
11. Turek Z, Grandtner M, Kubát K, Ringnalda BEM, Kreuzer F. Arterial blood gases, muscle fiber diameter and intercapillary distance in cardiac hypertrophy of rats with an old myocardial infarction. Pflügers Arch 1978;376:215.
12. Hernandez I, Cowley AW Jr, Lombard JH, Greene S. Salt intake and angiotensin II alter microvessel density in cremaster muscle of normal rats. Am J Physiol 1992;263 (Heart Circ. Physiol.):H664-H667.
13. Hernandez I, Cowley AW Jr, Lombard JH, Greene S. Salt intake and angiotensin II alter microvessel density in cremaster muscle of normal rats. Am J Physiol 1992;263 (Heart Circ. Physiol.):H664-H667.
14. Fernandez LA, Twicker J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985;105:141-145.
15. Canby CA, Tomanek RJ. Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy. Am J Physiol 1989;257 (Heart Circ. Physiol.):H1110-H1118.
16. Canby CA, Tomanek RJ. Role of lowering arterial pressure on maximal coronary flow with and without regression of cardiac hypertrophy. Am J Physiol 1989;257 (Heart Circ. Physiol.):H1110-H1118.
17. Unger T, Mattfeldt T, Lamberty V, Bock P, Mall G, Linz W, Schoulkens BA, Gohlke P. Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension 1992;20:478-482.
18. Schieffer B, Wirger A, Meybrun M, Seitz S, Holtz J, Riede UN, Drexler H. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type I receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-2282.
19. Fan T-PD, Hu DE. Losartan (DuP 753) blocks the angiogenic effect of angiotensin II in rats. FASEB J 1992;6:A937.
20. Smith RD, Chiu AT, Wong PC, Herblin WF, Timmermans PBMWM. Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol 1992;32:135-165.
21. Mirsky I, Pasipoularides A. Clinical assessment of diastolic function. Prog Cardiovasc Dis 1990;32:291-318.
22. Rakusan K, Turek Z. Protamine inhibits capillary formation in growing rat hearts. Circ Res 1985;37:393-399.
23. Lojda Z. Studies on dipeptidyl (amino) peptidase IV (glycilproline naphtyl-amidase). Histochemistry 1979;59:153-166.
24. Turek Z, Hoofd L, Rakusan K. Myocardial capillaries and tissue oxygenation. Can J Cardiol 1986;2:98-103.
25. Rakusan K, Korecky B, Sarkar K, Turek Z. Merits and pitfalls in morphological assessment of cardiac growth. Fed Proc 1986;45: 2580-2584.
26. Fishbein MC, MacLean D, Maroko PR. Experimental myocardial infarction in the rat: qualitative and quantitative changes during pathologic evolution. Am J Pathol 1978;90:57-70.
27. Olivetti G, Ricci R, Beghi C, Guideri G, Anversa P. Response of the border zone to myocardial infarction in rats. Am J Pathol 1986;125: 476-483.
28. Nishikimi T, Yamagishi H, Takeuchi T, Takeda T. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. Cardiovasc Res 1995;29:856-861.
29. Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin-converting enzyme inhibition improves cardiac function. Hypertension 1994;23:411-418.
30. Raya TE, Fonken SJ, Lee RW, Daugherty S, Goldman S, Wong PC, Timmermans PBMWM, Morkin E. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of cardiac failure. Am J Hypertens 1991;4:334S-340S.
31. Capasso JM. Angiotensin antagonists in models of heart failure. In: Saavedra JM, Timmermans PBMWM, eds. Angiotensin Receptors. New York: Plenum Press, 1994:255-286.
32. Feolde E, Vigne P, Frelin C. Angiotensin II receptor subtypes and biological responses in the rat heart. J Mol Cell Cardiol 1993;25: 1359-1367.
33. Brink M, de Gaspato M, Rogg H, Whitebread S, Bullock G. Localization of angiotensin II receptor subtypes in the rabbit heart. J Mol Cell Cardiol 1995;27:459-470.
34. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-657.
35. Reddy ST, Herschman HR. Ligand-induced prostaglandin synthesis requires expression of the TIS 10/PGS-2 prostaglandin synthase gene in murine fibroblasts and macrophages. J Biol Chem 1994; 269:15473-15480.